AIDS vaccine: Present status and future challenges

Indian Journal of Dermatology, Venereology and Leprology

Volumn 72, Issue 1, 2006, Pages 8-18

  Nigam, P K ^a   Kerketta, Manjula ^a  

^a PT J N M MEDICAL COLLEGE   (India)

Author keywords

AIDS; Clinical trials; HIV; Obstacles; Vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; T LYMPHOCYTE RECEPTOR; VIRUS VACCINE; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; B LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLADISTICS; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG HALF LIFE; EFFECTOR CELL; ENDOCYTOSIS; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC VARIABILITY; GLYCOSYLATION; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; PROTEIN PURIFICATION; REVIEW; T LYMPHOCYTE; UPREGULATION; VACCINATION; VIRUS IMMUNITY; VIRUS PARTICLE; VIRUS RECOMBINANT;

EID: 32044438197     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.19711     Document Type: Review

References (50)

1. Goudsmit J, Boucher CA, Meloen RH, Epstein LG, Smit L, van der Hoek L, et al. Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS 1988;2:157-64.
2. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-88.
3. Burton DR, Williamson RA, Parren PW. Antibody and virus: binding and neutralization. Virology 2000;270:1-3.
4. Ada G, Leung KN, Erti H. An analysis of effector T cell generation and function in mice exposed to influenza A or Sendai viruses. Immunol Rev 1981;58:5-24.
5. Sethi KK, Omata Y, Schneweis KE. Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. J Gen Virol 1983;64:443-7.
6. Siliciano RF, Lawton T, Knall C, Karr RW, Berman P, Gregory T, et al. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 1988;54:561-75.
7. Reimann KA, Tenner RK, Racz P, Montefiori DC, Yasutomi Y, Lin W, et al. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994;68:2362-70.
8. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Tong-Ming F, Wagner W, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92.
9. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, Troop M, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997;94:1890-5.
10. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994;271:42-6.
11. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332:228-32.
12. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50.
13. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, et al. Augmentation of human immunodeficiency virus type1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinianaive adults. The NIAID AIDS vaccine clinical trials network. J Infect Dis 1993;167:533-7.
14. Berman PW, Huang W, Riddle L, Gray AM, Wrin T, Vennari J, et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 1999;265:1-9.
15. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996;173:340-8.
16. Graham BS, Keefer MC, McElrath MJ, Gorse GJ, Schwartz DH, Weinhold K, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120 - a randomized, double-blind trial. Ann Intern Med 1996;125:270-9.
17. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS vaccine clinical trials network. JAMA 1994;272:475-80.
18. Corey L, McElrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, et al. Cytotoxic T cell and neutralizing antibody responses to HIV-1 envelope with a combination vaccine regimen. J Infect Dis 1998;177:301-9.
19. Gorse GJ, Patel GB, Newman FK. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. Clin Diag Lab Immunol 1996;3:378-86.
20. Clements-Mann ML, Matthews TJ, Weinhold K. HIV-1 immune responses induced by canarypox (ALVAC)-gp160 MN, SF-2 rgp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-46.
21. Evans TG, Keefer MC, Weinhold KJ, Wolff M, Montefiori DM, Corse GJ, et al. A canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120 elicits broad and durable CD8+ CTL responses in seronegative volunteers. J Infect Dis 1999;180:290-98.
22. El-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis 1993;168:306-13.
23. Ferrari G, Humphrey W, McElrath MJ. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-401.
24. Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, et al. Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. J Infect Dis 2000;181:897-903.
25. Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, et al. HIV-1 envelope-elicited neutralizing antibody titers correlate with protection and virus load in chimpanzees. Vaccine 1994;12:1141-8.
26. Schmitz JE, Kuroda MJ, Santra S, Simon MA, Lifton MA, Lin W, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003;77:2165-73.
27. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:678-82.
28. Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998;4:679-84.
29. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-12.
30. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100:4144-9.
31. Zolla-Pazner S, Sharon M, Kessier N, Levy R, Görlach M, Anglister J. Alternative conformations of HIV-1 V3 loops mimic b hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 2003;11:225-36.
32. Quinones-Kochs MI, Buonocore L, Rose JK. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 2002;76:4199-211.
33. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5.
34. Baig J, Levy DB, McKay PF, Schmitz JE, Santra S, Subbramanian RA, et al. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 2002;76:1484-90.
35. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49.
36. Ramsburg E, Rose NF, Mefford M, Haglund K, Buonocore L, Nixon DF, et al. A single VSV/SHIV immunization followed by one heterologous MVA/SHIV boost results in effective control of peak virus load after SHIV challenge. AIDS 2003;17:S117-24.
37. Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS 2000;14:1515-22.
38. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-92.
39. Chakrabarti BK, Kong WP, Wu BY, Yang ZY, Friborg J, Ling X, et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002;76:5357-68.
40. Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-52.
41. Cohen J. AIDS vaccine trial produces disappointment and confusion. Science 2003;299:1290-1.
42. Calarota SA, Leandersson AC, Bratt G, Hinkula J, Klinman M, Weinhold KJ, et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 1999;163:2330-8.
43. Kahn P. Update on Mercks AIDS vaccine program. IAVI Report February April 2003.
44. Quoted by Calarota SA, Weiner DB. Present status of human HIV vaccine development. AIDS 2003;17:S73-S84.
45. Gupta K, Hudgens M, Corey L, McElrath J, Weinhold K, Montefiori DC, et al. Safety and immunogenicity of a high-titred canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002;29:254-61.
46. Ratto-Kim S, Loomis-Price LD, Aronson N, Grimes J, Hill C, Williams C, et al. Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV (vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults. J Acquir Immune Defic Syndr 2003;32:9-17.
47. Wee EG, Patel S, McMichael AJ, Hanke T. A DNA/MVA-based candidate human immunodeficiency virus vaccine induces multi-specific T cell responses in rhesus macaques. J Gen Virol 2002;83:75-80.
48. Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, et al. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine 2002;20:1995-8.
49. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
50. Quoted by Newman MJ. Heterologous prime-boost vaccination strategies for HIV-1: Augmenting cellular immune responses. Curr Opin Invest Drugs 2002;3:374-8.